Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Caskin-1 (CASKIN1) is a large multidomain neuronal scaffolding and adaptor protein, predominantly expressed in brain tissue at both presynaptic and postsynaptic sites. It contains an N-terminal ankyrin repeat region, an atypical SH3 domain, two central tandem sterile-alpha motif (SAM) domains, and a C-terminal proline-rich region. Caskin-1 is notable for its interaction with the multidomain scaffolding protein CASK, via a short, conserved peptide motif, enabling the assembly of tripartite synaptic complexes essential for synaptic adhesion and neurotransmitter release. Its SAM domains can self-assemble into helical polymers, contributing to the organization and clustering of synaptic proteins at active zones. Besides CASK, Caskin-1 interacts with proteins such as neurexins, LAR family receptor protein tyrosine phosphatases, Dock, synaptotagmin, and others, suggesting a role in synaptic structure, function, and plasticity. Altered expression of Caskin-1 has been associated experimentally with neurodevelopmental and possibly epileptic phenotypes, although it is not currently a direct therapeutic target or known to have drug interactions[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Caskin-1 (CASKIN1).